Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome

Journal of the American Society of Nephrology

Volumn 25, Issue 1, 2014, Pages 55-64

  Bu, Fengxiao ^a   Maga, Tara ^a   Meyer, Nicole C ^a   Wang, Kai ^a   Thomas, Christie P ^a,b   Nester, Carla M ^a,b   Smith, Richard J H ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C2; COMPLEMENT FACTOR H; PLASMINOGEN;

ACUTE KIDNEY FAILURE; ARTICLE; BLOOD CLOTTING FACTOR 12 DEFICIENCY; CELL SURFACE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC ANALYSIS; HEMOLYTIC UREMIC SYNDROME; HETEROZYGOSITY; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNTRANSLATED REGION; VON WILLEBRAND DISEASE;

EID: 84891753035     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013050453     Document Type: Article

References (56)

1. Noris M, Remuzzi G: Atypical hemolytic-uremic syndrome. N Engl J Med 361: 1676-1687, 2009
2. Loirat C, Frémeaux-Bacchi V: Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6: 60, 2011
3. Zimmerhackl LB, Besbas N, Jungraithmayr T, van de Kar N, Karch H, Karpman D, Landau D, Loirat C, Proesmans W, Prüfer F, Rizzoni G, Taylor MC; European Study Group for Haemolytic Uraemic Syndromes and Related Disorders: Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost 32: 113-120, 2006
4. Constantinescu AR, Bitzan M,Weiss LS, Christen E, Kaplan BS,Cnaan A, Trachtman H: Non-enteropathic hemolytic uremic syndrome: Causes and short-term course. Am J Kidney Dis 43: 976-982, 2004
5. Le Quintrec M, Roumenina L, Noris M, Frémeaux-Bacchi V: Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. Semin Thromb Hemost 36: 641-652, 2010
6. Kavanagh D, Goodship T: Genetics and complement in atypical HUS. Pediatr Nephrol 25: 2431-2442, 2010
7. Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, Turnpenny P,Goodship JA: Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 53: 836-844, 1998
8. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, Loirat C, Rondeau E, Fridman WH: Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 41: e84, 2004
9. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Müslümanoglu MH, Kavukcu S, FillerG, Pirson Y,Wen LS, Atkinson JP, Goodship TH: Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 100: 12966-12971, 2003
10. Noris M, Brioschi S, Caprioli J, TodeschiniM, Bresin E, Porrati F,Gamba S, RemuzziG; International Registry of Recurrent and FamilialHUS/TTP: Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362: 1542-1547, 2003
11. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, López-Trascasa M, Sánchez-Corral P, Morgan BP, Rodríguez de Córdoba S: Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 104: 240-245, 2007
12. Frémeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL,MoghalN, Kaplan BS,Weiss RA, Lhotta K, KapurG,Mattoo T,Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJ, Goodship TH, Atkinson JP:Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112: 4948-4952, 2008
13. Sartz L, Olin AI, Kristoffersson AC, Ståhl AL, JohanssonME, Westman K, Fremeaux-Bacchi V,Nilsson-Ekdahl K, KarpmanD:AnovelC3mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. J Immunol 188: 2030-2037, 2012
14. Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, NorisM; EuropeanWorking Party on Complement Genetics in Renal Diseases: Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.JAm Soc Nephrol 24: 475-486, 2013
15. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L, López-Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S: Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 14: 703-712, 2005
16. Ermini L, Goodship TH, Strain L, Weale ME, Sacks SH, Cordell HJ, Fremeaux-Bacchi V, Sheerin NS: Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol 49: 640-648, 2012
17. Pickering MC, de Jorge EG,Martinez-Barricarte R, Recalde S,Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Córdoba SR, Botto M: Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 204: 1249-1256, 2007
18. Venables JP, Strain L, Routledge D, Bourn D, Powell HM,Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M, Pirson Y, Jackson MS, Hughes A,Wood KM, Goodship JA, Goodship TH: Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 3: e431, 2006
19. Zipfel PF, EdeyM, Heinen S, Józsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE,Goodship JA, Licht C, Goodship TH, Skerka C: Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 3: e41, 2007
20. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ: Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115: 379-387, 2010
21. Desch K, Motto D: Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome?JAmSoc Nephrol 18: 2457-2460, 2007
22. Motto D: Endothelial cells and thrombotic microangiopathy. Semin Nephrol 32: 208-214, 2012
23. Delvaeye M, NorisM, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM: Thrombomodulin mutations in atypical hemolyticuremic syndrome. N Engl J Med 361: 345-357, 2009
24. Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le QuintrecM, Fakhouri F, Taque S, Nobili F,Martinez F, Ji W,Overton JD, Mane SM, Nürnberg G, Altmüller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nürnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP: Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45: 531-536, 2013
25. Sadler JE: Thrombomodulin structure and function. Thromb Haemost 78: 392-395, 1997
26. Schuster V, Seidenspinner S, Zeitler P, Escher C, Pleyer U, BernauerW, Stiehm ER, Isenberg S, Seregard S, Olsson T, Mingers AM, Schambeck C, Kreth HW: Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis. Blood 93: 3457-3466, 1999
27. Tefs K, Tait CR, Walker ID, Pietzsch N, Ziegler M, Schuster V: A K19E missense mutation in the plasminogen gene is a common cause of familial hypoplasminogenaemia. Blood Coagul Fibrinolysis 14: 411-416, 2003
28. Tefs K, Gueorguieva M, Klammt J, Allen CM, Aktas D, Anlar FY, Aydogdu SD, Brown D, Ciftci E, Contarini P, Dempfle CE, DostalekM, Eisert S,Gökbuget A,GünhanO, Hidayat AA,Hügle B, IsikogluM, Irkec M, Joss SK, Klebe S, Kneppo C, Kurtulus I, Mehta RP, Ornek K, Schneppenheim R, Seregard S, Sweeney E, Turtschi S, Veres G, Zeitler P, Ziegler M, Schuster V: Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patients. Blood 108: 3021-3026, 2006
29. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA. Available at: http://evs.gs.washington.edu/EVS/. Accessed December 1, 2012
30. Schloesser M, Hofferbert S, Bartz U, Lutze G, Lämmle B, Engel W: The novel acceptor splice site mutation 11396(G-.A) in the factor XII gene causes a truncated transcript in cross-reacting material negative patients. Hum Mol Genet 4: 1235-1237, 1995
31. Chegeni R, Vickars L, Favaloro EJ, Lillicrap D, Othman M: Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease. Thromb Res 127: 161-166, 2011
32. Ohlin AK, Norlund L, Marlar RA: Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost 78: 396-400, 1997
33. Ohlin AK, Marlar RA: Thrombomodulin gene defects in families with thromboembolic disease-a report on four families. Thromb Haemost 81: 338-344, 1999
34. Modde F, Agustian PA, Wittig J, DammrichME, Forstmeier V, Vester U, Ahlenstiel T, Froede K, Budde U, Wingen AM, Schwarz A, Lovric S, Kielstein JT, Bergmann C, Bachmann N, Nagel M, Kreipe HH, Brocker V, Bockmeyer CL, Becker JU: Comprehensive analysis of glomerular mRNA expression of pro-and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS). Virchows Arch 462: 455-464, 2013
35. ChandlerWL, Jelacic S, Boster DR, CiolMA, Williams GD, Watkins SL, Igarashi T, Tarr PI: Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 346: 23-32, 2002
36. Proesmans W: The role of coagulation and fibrinolysis in the pathogenesis of diarrhea-associated hemolytic uremic syndrome. Semin Thromb Hemost 27: 201-205, 2001
37. Van Geet C, Proesmans W, Arnout J, Vermylen J, Declerck PJ: Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. Kidney Int 54: 1324-1330, 1998
38. KruezW, Linde R, Becker S, Seifried E: Successful treatment of haemolytic uraemic syndrome with recombinant tissue-type plasminogen activator. Lancet 341: 1665-1666, 1993
39. Bergstein JM, Riley M, Bang NU: Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 327: 755-759, 1992
40. Józsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C: Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111: 1512-1514, 2008
41. Frimat M, Tabarin F, Dimitrov JD, Poitou C, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT: Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 122: 282-292, 2013
42. Shearer AE, Hildebrand MS, Smith RJ: Solution-based targeted genomic enrichment for precious DNA samples. BMC Biotechnol 12: 20, 2012
43. Nielsen R, Paul JS, Albrechtsen A, Song YS: Genotype and SNP calling from next-generation sequencing data. Nat Rev Genet 12: 443-451, 2011
44. Goecks J, Nekrutenko A, Taylor J; Galaxy Team: Galaxy: A comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol 11: R86, 2010
45. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA; 1000 Genomes Project Consortium: A map of human genome variation from population-scale sequencing. Nature 467: 1061-1073, 2010
46. Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U: A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet 38: 1173-1177, 2006
47. Schmid-Kubista KE, Tosakulwong N, Wu Y, Ryu E, Hecker LA, Baratz KH, Brown WL, Edwards AO: Contribution of copy number variation in the regulation of complement activation locus to development of agerelated macular degeneration. Invest Ophthalmol Vis Sci 50: 5070-5079, 2009
48. Ahn JW,Ogilvie CM,Welch A, Thomas H,Madula R, Hills A, Donaghue C, Mann K: Detection of subtelomere imbalance using MLPA: Validation, development of an analysis protocol, and application in a diagnostic centre. BMC Med Genet 8: 9, 2007
49. González JR, Carrasco JL, Armengol L, Villatoro S, Jover L, Yasui Y, Estivill X: Probe-specific mixed-model approach to detect copy number differences using multiplex ligation-dependent probe amplification (MLPA). BMC Bioinformatics 9: 261, 2008
50. Witzel-Schlömp K, Späth PJ, Hobart MJ, Fernie BA, Rittner C, Kaufmann T, Schneider PM: The human complement C9 gene: Identification of two mutations causing deficiency and revision of the gene structure. J Immunol 158: 5043-5049, 1997
51. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ: Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31: E1445-E1460, 2010
52. Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, Arzouk N, Cleper R, Francois M, Guest G, Pourrat J, Seligman R, FridmanWH, Loirat C, Atkinson JP: Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 17: 2017-2025, 2006
53. Manuelian T, Hellwage J, Meri S, Caprioli J, NorisM, Heinen S, Jozsi M, Neumann HP, Remuzzi G, Zipfel PF: Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 111: 1181-1190, 2003
54. Ståhl AL, Vaziri-Sani F,Heinen S, Kristoffersson AC,Gydell KH, Raafat R, Gutierrez A, Beringer O, Zipfel PF, Karpman D: Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 111: 5307-5315, 2008
55. Jalanko H, Peltonen S, Koskinen A, Puntila J, Isoniemi H, Holmberg C, Pinomaki A, Armstrong E, Koivusalo A, Tukiainen E,Makisalo H, Saland J, Remuzzi G, de Cordoba S, Lassila R, Meri S, Jokiranta TS: Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant 8: 216-221, 2008
56. Gaucher C, Mercier B, Jorieux S, Oufkir D, Mazurier C: Identification of two point mutations in the vonWillebrand factor gene of three families with the 'Normandy' variant of von Willebrand disease. Br J Haematol 78: 506-514, 1991